Aldeyra is downgraded from Buy to Hold due to high risk ahead of reproxalap's December PDUFA for dry eye disease. ALDX faces regulatory uncertainty after two FDA CRLs, with recent mixed trial results ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results